Severe Combined Immunodeficiency Due to ADA Deficiency
A rare inherited metabolic and immune disorder causing absent T, B, and NK cells, treatable with enzyme replacement, gene therapy, or transplant.
- Gene therapy approved
- Enzyme replacement available
- Newborn screening detectable
- Most Common In
- Infants, autosomal recessive inheritance
- Typical Onset
- First weeks to months of life
- Affected Gene
- ADA (adenosine deaminase)
- Advanced Therapies
- Gene therapy, PEG-ADA enzyme replacement
What Is ADA-SCID?
ADA-SCID is a rare, severe form of Severe Combined Immunodeficiency caused by mutations in the ADA gene, which encodes the enzyme adenosine deaminase. This enzyme normally clears toxic metabolic byproducts (deoxyadenosine and its derivatives) that, when allowed to accumulate, are especially harmful to developing lymphocytes. The result is a profound and unusual deficiency affecting T cells, B cells, and NK cells, distinguishing it from many other SCID subtypes that spare B or NK cells.
Because the underlying defect is metabolic as well as immunologic, infants with ADA-SCID may also show skeletal, neurologic, and hearing abnormalities related to toxin accumulation outside the immune system, in addition to severe susceptibility to infection.
ADA-SCID is inherited in an autosomal recessive pattern, meaning both parents typically carry one altered copy of the gene without being affected themselves. Early diagnosis, often via newborn screening, allows treatment to begin before life-threatening infection or organ damage occurs.
Clinical Variants
ADA deficiency exists on a spectrum based on residual enzyme activity, which influences age of onset and severity.
Symptoms and Warning Signs
Infants with ADA-SCID typically develop severe infections early in life, sometimes accompanied by non-immune features related to metabolic toxin buildup.
Causes and Risk Factors
ADA-SCID is a purely genetic condition with no known environmental or lifestyle contributors.
Diagnosis and Investigations
Diagnosis combines newborn screening, immune function testing, and direct measurement of enzyme activity or gene sequencing.
Disease Severity Stratification
ADA-SCID is stratified by residual enzyme activity and clinical status rather than a formal staging system.
Standard Treatment Approach
Treatment for ADA-SCID combines enzyme replacement to stabilize the infant with a definitive curative approach โ gene therapy or stem cell transplant.
Advanced and Emerging Treatment Options
Gene therapy has become a leading curative option for ADA-SCID, particularly when no matched donor is available.
Gene Therapy
Lentiviral vector-mediated ADA gene therapy
Autologous hematopoietic stem cells are corrected with a functional ADA gene and reinfused, restoring enzyme activity and immune function without a donor.
Enzyme Replacement
PEG-ADA enzyme replacement therapy
Used as a bridge therapy to stabilize patients before definitive treatment, or as longer-term management when transplant or gene therapy is not yet feasible.
Cellular Therapy
Matched or haploidentical hematopoietic stem cell transplant
Remains a well-established curative option, particularly when a matched sibling donor is available.
Biomarkers and Precision Testing
Biochemical and genetic markers are central to diagnosing ADA-SCID and tracking response to treatment.
When a Second Opinion May Be Important
Given the dual immunologic and metabolic nature of ADA-SCID, specialist input can meaningfully change management.
Clinical Trials and Research
Prognosis and Key Outcome Factors
With early diagnosis and access to enzyme replacement, gene therapy, or transplant, outcomes for ADA-SCID have improved substantially over the past two decades.
Supportive Care and Living With ADA-SCID
Because ADA deficiency affects more than the immune system, supportive care extends beyond infection prevention.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families of children with ADA-SCID access specialist immunology review, coordinate urgent referrals for enzyme replacement, and connect with centers offering gene therapy or transplant programs.
Get a free case reviewFrequently Asked Questions
ADA-SCID is a severe inherited immunodeficiency caused by mutations in the ADA gene, leading to absent T, B, and NK cells and toxic buildup of metabolic byproducts.
Early signs include recurrent infections, chronic diarrhea, poor growth, and in some infants skeletal or hearing abnormalities.
Yes โ gene therapy and hematopoietic stem cell transplant can both provide durable cures, with enzyme replacement used to stabilize patients in the meantime.
PEG-ADA is an enzyme replacement therapy that reduces toxic metabolite buildup and partially restores immune function, often used as a bridge to definitive treatment.
ADA-SCID is unique in causing a systemic metabolic toxicity that affects T, B, and NK cells together, whereas some other SCID subtypes spare B or NK cells.
Yes โ TREC-based newborn screening can detect the severe T-cell lymphopenia seen in ADA-SCID before symptoms appear.
Yes โ some children have associated skeletal abnormalities, hearing loss, or developmental delay related to toxin accumulation outside the immune system.
Genetic counseling and carrier testing are recommended for parents and siblings to guide future family planning.
Gene therapy using the patient's own corrected stem cells is an option that does not require a matched donor.
Yes. CancerFax can help coordinate medical report review, connect families with specialist immunology and transplant centers, support second opinion requests, and facilitate access to gene therapy programs, including cross-border coordination when needed.
Get Expert Guidance on ADA-SCID Treatment
Our team can help you connect with specialist immunology and transplant centers for urgent evaluation and treatment planning.